Maxillary Sinus Elevation With Bio-Oss or Straumann BoneCeramic
NCT ID: NCT00901121
Last Updated: 2016-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
48 participants
INTERVENTIONAL
2005-07-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Straumann Bone Ceramic Versus BioOss in Sinus Elevation
NCT00900822
Transcrestal Sinus Lift With OSSIX Bone vs BIOSS Collagen
NCT07041411
Implants Placed With Crestal Sinus Approach Versus Osseodensification in Atrophic Posterior Maxilla
NCT06207578
Bioactive Surfaces vs. Conventional Surfaces in Implants Placed in Atrophic Maxilla With Simultaneous Sinus Lift
NCT05500911
A Histomorphometric Analysis Following Sinus Augmentation Using Two Different Bone Graft Materials.
NCT03059914
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In total 13 visits per patient are scheduled in this study.
The study device Straumann Bone Ceramic is CE-marked.
Height centers in Italy will participate.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BoneCeramic
Straumann BoneCeramic is a fully synthetic bone graft substitute of medical grade purity in particulate form composed of biphasic calcium phosphate - a mixture of 60% hydroxylapatite and of 40% of the beta form of tricalcium phosphate (beta-TCP).
Straumann BoneCeramic
Straumann BoneCeramic (500-1000 microns, 0.5g)
Bio-Oss
Bio-Oss spongiosa granules, size of particle 0.25-1 mm
Bio-Oss
Bio-Oss spongiosa granules, size of particle 0.25-1 mm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Straumann BoneCeramic
Straumann BoneCeramic (500-1000 microns, 0.5g)
Bio-Oss
Bio-Oss spongiosa granules, size of particle 0.25-1 mm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A dental implant procedure was foreseen in the maxilla region corresponding to maxillary sinus
* Patients presented a bone defect in the sinus area, which needed a sinus floor elevation to place one or more dental implants
* The patients were unilaterally or bilaterally edentulous in the maxillary region corresponding to the sinuses
* Residual alveolar crest height of the lateral-posterior segments of the edentulous maxilla below the floor of the maxillary sinus was less than 8 mm and at least 3 mm, measured by CT scans. Furthermore, residual alveolar crest width should be at least in average 6 mm measured by the CT scans
* Patients were committed to the study
* Patients were healthy at time of surgery
Exclusion Criteria
* Standard blood test performed by the medical practitioner of the patient showing: leukocyte dysfunction and deficiencies
* Haemophilia, bleeding disorders or cumarin therapy
* History of neoplastic disease requiring the use of chemotherapy
* History of radiation therapy to the head and neck
* Patients with history of renal failure or chronic renal diseases
* Patients affected by chronic liver diseases
* Patients with severe or uncontrolled metabolic bone disorders
* Uncontrolled endocrine disorders (including diabetes)
* Current pregnancy at the time of recruitment
* Physical handicaps that would interfere with the ability to perform adequate oral hygiene
* Use of any investigational drug or device within the 90 days period immediately prior to implant surgery on study day 0
* Alcoholism or chronically drug abuse causing systemic compromisation
* Immunocompromised patients including patients infected with HIV
* Patients who smoke more than 10 cigarettes per day or cigar equivalents, or who chew tobacco
* Conditions or circumstances, in the opinion of the investigator, which could represent a general contra-indication for surgical procedure or would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, or unreliability
* Local inflammation, including untreated periodontitis to residual dentition
* Mucosal diseases such as erosive lichen planus
* History of local radiation therapy
* Presence of oral lesions (such as ulceration, malignancy)
* Severe bruxing or clenching habits
* Persistent intraoral infection
* Patients with inadequate oral hygiene or unmotivated for adequate home care
* Unhealed extraction sites in the upper premolar or molar area
* Last tooth extraction performed less than 3 months before surgery 1
* Previous GBR (guided bone regeneration) or dental implant treatment in the lateral-posterior segments of the upper maxilla (foreseen implant site)
* Patients presenting clinical and radiological signs and symptoms of maxillary sinus disease
* Patients presenting with residual alveolar crest height of the lateral-posterior segments of the edentulous maxilla below the floor of the maxillary sinus less than 3 mm and residual alveolar crest width less than 6 mm (measured by the CT scans)
* The reduction in residual bone height was determined by sinus pneumatization and not by vertical resorption of the residual alveolar crest with increased interarch distance. Patients with increased interarch distance were excluded from the study
* Existing teeth in the residual dentition with untreated endodontic or cariologic problems
* Horizontal or vertical augmentation to correct the vertical inter-arch distance or to correct horizontal defects
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Straumann AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matteo Chiapasco, Prof
Role: PRINCIPAL_INVESTIGATOR
University of Milan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Private Practice
Milan, , Italy
University of Milan
Milan, , Italy
Private Practice
Naples, , Italy
Private Practice
Naples, , Italy
Private Practice
Pavia, , Italy
Private Practice
Rome, , Italy
Private Practice
Rome, , Italy
Eastman Dental Hospital ASL RMA Roma
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cordaro L, Bosshardt DD, Palattella P, Rao W, Serino G, Chiapasco M. Maxillary sinus grafting with Bio-Oss or Straumann Bone Ceramic: histomorphometric results from a randomized controlled multicenter clinical trial. Clin Oral Implants Res. 2008 Aug;19(8):796-803. doi: 10.1111/j.1600-0501.2008.01565.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CR 09/04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.